ACT34-CLI, bone marrow-derived cells for critical limb ischemia
ACT34 are autologous bone marrow-derived CD34+ cells. ACT34 is used to treat critical limb ischemia (CLI). The CD34+ cells are injected back into the patient and result in lower amputation incidence.
Read More
There is a phase II clinical trial ongoing since Nov 20, 2007.
Read More
Product Information for
ACT34-CLI, bone marrow-derived cells for critical limb ischemia